Nascent Biotech EBITDA TCAC 5A

Que fait Nascent Biotech ? Nascent Biotech, Inc. develops monoclonal antibodies for cancer treatment, focusing on drug candidates in early clinical stages. The company's primary product, Pritumumab, targets epithelial cancers including lung, breast, colon, brain, and pancreas cancers, with initial emphasis on brain malignancies like glioblastoma and malignant astrocytoma. Nascent Biotech explores Pritumumab's potential against viruses and is developing a traditional vaccine platform for viral infections. The company generates revenue through the development and commercialization of its biologic drug candidates, targeting healthcare providers and pharmaceutical partners for future licensing or sales. Nascent Biotech's business model centers on advancing clinical-stage drug candidates toward commercialization, leveraging its monoclonal antibody technology. The firm's focus on Pritumumab for epithelial cancers and its vaccine platform represents key revenue streams. By targeting specific cancer types and viral infections, Nascent Biotech aims to secure partnerships with pharmaceutical companies for drug development and distribution. The company's revenue streams include potential licensing agreements for Pritumumab and its vaccine platform, as well as future sales of approved treatments. Nascent Biotech's target customers are healthcare institutions and pharmaceutical firms seeking innovative cancer therapies and viral vaccines. The company's strategy involves progressing its drug candidates through clinical trials to attract commercial partnerships and eventual market entry. Nascent Biotech est l'une des entreprises les plus populaires sur Eulerpool.